What is the projected market valuation of the Lung In-vitro Model Market by 2035?

The Lung In-vitro Model Market is projected to reach a valuation of 4.811 USD Billion by 2035. Read More

What was the market valuation of the Lung In-vitro Model Market in 2024?

In 2024, the Lung In-vitro Model Market was valued at 0.7994 USD Billion. Read More

What is the expected CAGR for the Lung In-vitro Model Market during the forecast period 2025 - 2035?

The expected CAGR for the Lung In-vitro Model Market during the forecast period 2025 - 2035 is 17.72%. Read More

Which companies are considered key players in the Lung In-vitro Model Market?

Key players in the Lung In-vitro Model Market include Emulate Inc, Mimetas, TissUse GmbH, InSphero AG, Organovo Holdings Inc, Synlogic Inc, Acelity L.P. Inc, and Reinnervate Ltd. Read More

What are the main types of Lung In-vitro Models and their market valuations?

The main types include 2D Lung In-vitro Models valued at 1.9235 USD Billion, 3D Lung In-vitro Models at 1.4426 USD Billion, and Co-Culture Lung In-vitro Models at 1.4449 USD Billion. Read More

What applications are driving the Lung In-vitro Model Market?

Key applications driving the market include Drug Discovery and Development valued at 1.9255 USD Billion and Toxicological Studies at 1.4446 USD Billion. Read More

Which diseases are primarily modeled using Lung In-vitro Models?

Diseases modeled include Chronic Obstructive Pulmonary Disease valued at 1.4391 USD Billion and Lung Cancer at 1.4397 USD Billion. Read More

What formats are available for Lung In-vitro Models and their respective market sizes?

Available formats include Fixed models valued at 1.9255 USD Billion, Frozen models at 1.4433 USD Billion, and Live models at 1.4422 USD Billion. Read More

Who are the primary end-users of Lung In-vitro Models?

Primary end-users include Pharmaceutical and Biotechnology Companies valued at 2.4055 USD Billion and Academic and Research Institutions at 1.4433 USD Billion. Read More

How does the market for Lung In-vitro Models compare across different segments?

The market shows varied valuations across segments, with Drug Discovery and Development leading at 1.9255 USD Billion, followed by Toxicological Studies at 1.4446 USD Billion. Read More

Lung In Vitro Model Market

ID: MRFR/HC/25543-HCR

128 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Lung In-vitro Model Market Research Report By Type (2D Lung In-vitro Model, 3D Lung In-vitro Model, Co-Culture Lung In-vitro Model), By Application (Drug Discovery and Development, Toxicological Studies, Personalized Medicine, Disease Modeling), By Disease Model (Idiopathic Pulmonary Fibrosis, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer), By Format (Frozen, Fixed, Live), By End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutions, Contract Research Organizations) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type (USD Billion)
  1. 4.1.1 2D Lung In-vitro Model
  2. 4.1.2 3D Lung In-vitro Model
  3. 4.1.3 Co-Culture Lung In-vitro Model
2. 4.2 Healthcare, BY Application (USD Billion)
  1. 4.2.1 Drug Discovery and Development
  2. 4.2.2 Toxicological Studies
  3. 4.2.3 Personalized Medicine
  4. 4.2.4 Disease Modeling
3. 4.3 Healthcare, BY Disease Model (USD Billion)
  1. 4.3.1 Idiopathic Pulmonary Fibrosis
  2. 4.3.2 Chronic Obstructive Pulmonary Disease
  3. 4.3.3 Asthma
  4. 4.3.4 Lung Cancer
4. 4.4 Healthcare, BY Format (USD Billion)
  1. 4.4.1 Frozen
  2. 4.4.2 Fixed
  3. 4.4.3 Live
5. 4.5 Healthcare, BY End-user (USD Billion)
  1. 4.5.1 Pharmaceutical and Biotechnology Companies
  2. 4.5.2 Academic and Research Institutions
  3. 4.5.3 Contract Research Organizations
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Emulate Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Mimetas (NL)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 TissUse GmbH (DE)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 InSphero AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Organovo Holdings Inc (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Synlogic Inc (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Acelity L.P. Inc (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Reinnervate Ltd (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE
4. 6.4 US MARKET ANALYSIS BY APPLICATION
5. 6.5 US MARKET ANALYSIS BY DISEASE MODEL
6. 6.6 US MARKET ANALYSIS BY FORMAT
7. 6.7 US MARKET ANALYSIS BY END-USER
8. 6.8 CANADA MARKET ANALYSIS BY TYPE
9. 6.9 CANADA MARKET ANALYSIS BY APPLICATION
10. 6.10 CANADA MARKET ANALYSIS BY DISEASE MODEL
11. 6.11 CANADA MARKET ANALYSIS BY FORMAT
12. 6.12 CANADA MARKET ANALYSIS BY END-USER
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY APPLICATION
16. 6.16 GERMANY MARKET ANALYSIS BY DISEASE MODEL
17. 6.17 GERMANY MARKET ANALYSIS BY FORMAT
18. 6.18 GERMANY MARKET ANALYSIS BY END-USER
19. 6.19 UK MARKET ANALYSIS BY TYPE
20. 6.20 UK MARKET ANALYSIS BY APPLICATION
21. 6.21 UK MARKET ANALYSIS BY DISEASE MODEL
22. 6.22 UK MARKET ANALYSIS BY FORMAT
23. 6.23 UK MARKET ANALYSIS BY END-USER
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY APPLICATION
26. 6.26 FRANCE MARKET ANALYSIS BY DISEASE MODEL
27. 6.27 FRANCE MARKET ANALYSIS BY FORMAT
28. 6.28 FRANCE MARKET ANALYSIS BY END-USER
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY APPLICATION
31. 6.31 RUSSIA MARKET ANALYSIS BY DISEASE MODEL
32. 6.32 RUSSIA MARKET ANALYSIS BY FORMAT
33. 6.33 RUSSIA MARKET ANALYSIS BY END-USER
34. 6.34 ITALY MARKET ANALYSIS BY TYPE
35. 6.35 ITALY MARKET ANALYSIS BY APPLICATION
36. 6.36 ITALY MARKET ANALYSIS BY DISEASE MODEL
37. 6.37 ITALY MARKET ANALYSIS BY FORMAT
38. 6.38 ITALY MARKET ANALYSIS BY END-USER
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY APPLICATION
41. 6.41 SPAIN MARKET ANALYSIS BY DISEASE MODEL
42. 6.42 SPAIN MARKET ANALYSIS BY FORMAT
43. 6.43 SPAIN MARKET ANALYSIS BY END-USER
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY DISEASE MODEL
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY FORMAT
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY END-USER
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE
51. 6.51 CHINA MARKET ANALYSIS BY APPLICATION
52. 6.52 CHINA MARKET ANALYSIS BY DISEASE MODEL
53. 6.53 CHINA MARKET ANALYSIS BY FORMAT
54. 6.54 CHINA MARKET ANALYSIS BY END-USER
55. 6.55 INDIA MARKET ANALYSIS BY TYPE
56. 6.56 INDIA MARKET ANALYSIS BY APPLICATION
57. 6.57 INDIA MARKET ANALYSIS BY DISEASE MODEL
58. 6.58 INDIA MARKET ANALYSIS BY FORMAT
59. 6.59 INDIA MARKET ANALYSIS BY END-USER
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY APPLICATION
62. 6.62 JAPAN MARKET ANALYSIS BY DISEASE MODEL
63. 6.63 JAPAN MARKET ANALYSIS BY FORMAT
64. 6.64 JAPAN MARKET ANALYSIS BY END-USER
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY DISEASE MODEL
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY FORMAT
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY END-USER
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY APPLICATION
72. 6.72 MALAYSIA MARKET ANALYSIS BY DISEASE MODEL
73. 6.73 MALAYSIA MARKET ANALYSIS BY FORMAT
74. 6.74 MALAYSIA MARKET ANALYSIS BY END-USER
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY APPLICATION
77. 6.77 THAILAND MARKET ANALYSIS BY DISEASE MODEL
78. 6.78 THAILAND MARKET ANALYSIS BY FORMAT
79. 6.79 THAILAND MARKET ANALYSIS BY END-USER
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY APPLICATION
82. 6.82 INDONESIA MARKET ANALYSIS BY DISEASE MODEL
83. 6.83 INDONESIA MARKET ANALYSIS BY FORMAT
84. 6.84 INDONESIA MARKET ANALYSIS BY END-USER
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY APPLICATION
87. 6.87 REST OF APAC MARKET ANALYSIS BY DISEASE MODEL
88. 6.88 REST OF APAC MARKET ANALYSIS BY FORMAT
89. 6.89 REST OF APAC MARKET ANALYSIS BY END-USER
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY APPLICATION
93. 6.93 BRAZIL MARKET ANALYSIS BY DISEASE MODEL
94. 6.94 BRAZIL MARKET ANALYSIS BY FORMAT
95. 6.95 BRAZIL MARKET ANALYSIS BY END-USER
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY APPLICATION
98. 6.98 MEXICO MARKET ANALYSIS BY DISEASE MODEL
99. 6.99 MEXICO MARKET ANALYSIS BY FORMAT
100. 6.100 MEXICO MARKET ANALYSIS BY END-USER
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY APPLICATION
103. 6.103 ARGENTINA MARKET ANALYSIS BY DISEASE MODEL
104. 6.104 ARGENTINA MARKET ANALYSIS BY FORMAT
105. 6.105 ARGENTINA MARKET ANALYSIS BY END-USER
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISEASE MODEL
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMAT
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY DISEASE MODEL
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY FORMAT
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END-USER
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY DISEASE MODEL
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY FORMAT
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END-USER
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY APPLICATION
124. 6.124 REST OF MEA MARKET ANALYSIS BY DISEASE MODEL
125. 6.125 REST OF MEA MARKET ANALYSIS BY FORMAT
126. 6.126 REST OF MEA MARKET ANALYSIS BY END-USER
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY DISEASE MODEL, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY DISEASE MODEL, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY FORMAT, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY FORMAT, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY END-USER, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.2.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.2.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.2.5 BY END-USER, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.3.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.3.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.3.5 BY END-USER, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.4.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.4.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.4.5 BY END-USER, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.5.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.5.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.5.5 BY END-USER, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.6.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.6.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.6.5 BY END-USER, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.7.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.7.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.7.5 BY END-USER, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.8.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.8.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.8.5 BY END-USER, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.9.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.9.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.9.5 BY END-USER, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.10.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.10.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.10.5 BY END-USER, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.11.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.11.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.11.5 BY END-USER, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.12.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.12.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.12.5 BY END-USER, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.13.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.13.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.13.5 BY END-USER, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.14.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.14.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.14.5 BY END-USER, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.15.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.15.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.15.5 BY END-USER, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.16.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.16.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.16.5 BY END-USER, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.17.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.17.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.17.5 BY END-USER, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.18.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.18.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.18.5 BY END-USER, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.19.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.19.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.19.5 BY END-USER, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.20.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.20.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.20.5 BY END-USER, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.21.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.21.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.21.5 BY END-USER, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.22.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.22.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.22.5 BY END-USER, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.23.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.23.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.23.5 BY END-USER, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.24.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.24.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.24.5 BY END-USER, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.25.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.25.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.25.5 BY END-USER, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.26.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.26.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.26.5 BY END-USER, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.27.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.27.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.27.5 BY END-USER, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.28.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.28.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.28.5 BY END-USER, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.29.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.29.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.29.5 BY END-USER, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE, 2025-2035 (USD Billion)
  2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
  3. 7.30.3 BY DISEASE MODEL, 2025-2035 (USD Billion)
  4. 7.30.4 BY FORMAT, 2025-2035 (USD Billion)
  5. 7.30.5 BY END-USER, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

2D Lung In-vitro Model
3D Lung In-vitro Model
Co-Culture Lung In-vitro Model

Healthcare By Application (USD Billion, 2025-2035)

Drug Discovery and Development
Toxicological Studies
Personalized Medicine
Disease Modeling

Healthcare By Disease Model (USD Billion, 2025-2035)

Idiopathic Pulmonary Fibrosis
Chronic Obstructive Pulmonary Disease
Asthma
Lung Cancer

Healthcare By Format (USD Billion, 2025-2035)

Frozen
Fixed
Live

Healthcare By End-user (USD Billion, 2025-2035)

Pharmaceutical and Biotechnology Companies
Academic and Research Institutions
Contract Research Organizations

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”